Drug Trial Radar · NCT04008797
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
301
Planned (sponsor's estimate)
Start
Jul 11, 2019
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
Conditions
- Endometrial Neoplasms
- Neoplasms
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Colorectal Neoplasms
Interventions
E7386Drug
E7386 dosing.
LenvatinibDrug
Lenvatinib dosing.
DoxorubicinDrug
Doxorubicin dosing.
PaclitaxelDrug
Paclitaxel dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Cycle 0 (Cycle 0 length=6 or 7 days) up to Cycle 1 (Cycle 1 length=28 days)
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (up to approximately 90 months)
- Dose Optimization Part: Objective Response Rate (ORR) per RECIST 1.1 by Investigator AssessmentTime frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 90 months)
Locations
106 sites in 10 countries. Site status is shown where the registry gives one.
UAMS
Little Rock, Arkansas
University of California San Diego (UCSD) - Moores Cancer Center(All)
La Jolla, California
Cedars-Sinai Medical Center
Los Angeles, California
Pasadena Liver Center
Pasadena, California
California Pacific Medical Center
San Francisco, California
UCLA University of California - Los Angeles
Santa Monica, California
John Muir Clinical Research
Walnut Creek, California
University of Colorado Cancer Center - Anschutz Medical Campus
Aurora, Colorado
Uni. Of Miami- Sylvester Cancer Centre
Miami, Florida
Florida Cancer Specialists - South
Sarasota, Florida
Florida Cancer Specialists - East
West Palm Beach, Florida
Women's Cancer Care - Covington, LA
Covington, Louisiana
University Of Mississippi Medical Center
Jackson, Mississippi
Kansas City Research Institute
Kansas City, Missouri
Perlmutter Cancer Center- NYU Langone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center (MMC) - Jack D. Weiler Hospital
The Bronx, New York
MetroHealth Medical Center
Cleveland, Ohio
ProMedica Flower Hospital
Sylvania, Ohio
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma
Medical University of South Carolina
Charleston, South Carolina
Sanford Cancer Centre
Sioux Falls, South Dakota
Tennessee Oncology
Nashville, Tennessee
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
University of Texas Southwestern Medical
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson/University of Washington Cancer Consortium
Seattle, Washington
Sunnybrook Research Institute
Toronto, Ontario, Canada
CHUM, Unit for Innovative Therapies
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Beijing Cancer Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
Fujian Provincial Cancer Hospital
Fuzhou, China
Sun Yan-sen University Cancer Center
Guangzhou, China
Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University
Guangzhou, China
Cancer Hospital of Shandong First Medical University
Jinan, China
Yunnan Cancer Hospital
Kunming, China
Fudan University Cancer Center
Shanghai, China
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.